Vaccitech plc (VACC)

The total asset value of Vaccitech plc (VACC) stood at $ 274 Mln as on 31-Mar-23

The share price of Vaccitech plc (VACC) is $1.680000 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Vaccitech plc (VACC) has given a return of -50% in the last 1 years.

Vaccitech plc (VACC) has a market capitalisation of $ 87 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Vaccitech plc (VACC) is 0.36 times as on 23-Jun-2023, a -0.86% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Vaccitech plc (VACC) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vaccitech plc (VACC) and enter the required number of quantities and click on buy to purchase the shares of Vaccitech plc (VACC).

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. V

The CEO & director of Mr. William J. Enright MBA. is Vaccitech plc (VACC), and CFO & Sr. VP is Dr. Margaret Marshall M.D..

The promoters of Vaccitech plc (VACC) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

Yes, TTM profit after tax of Vaccitech plc (VACC) was $24 Mln.